Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03796559 · ClinicalTrials.gov registry record · NA

Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

A NA study of Breast Cancer and Axillary Lymph Nodes, sponsored by Endomagnetics.

Recruiting
Registry status
NA
Development phase
65
Enrollment target
2
Study locations

NCT03796559 is a NA study of Breast Cancer and Axillary Lymph Nodes that is actively recruiting participants, run by Endomagnetics. The registered enrollment target is 65 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03796559, a NA study of Breast Cancer and Axillary Lymph Nodes, is actively recruiting participants, sponsored by Endomagnetics.

RECRUITING
Registry status
NA
Development phase
65 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to provide prospective evidence that the use of Magseed/Sentimag in marking axillary lymph nodes and guiding surgical localization in patients with breast cancer following neo-adjuvant chemotherapy (NAC) is effective.

Interventions

  • DEVICE Magseed Marker

Study Locations (2)

Texas

  • Baylor Medicine - Houston
  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2019-06-13
Est. Completion 2026-05
Phase NA

Sponsor

Endomagnetics

4 total trials

What the Registry Record Tells You About NCT03796559

The ClinicalTrials.gov registry entry for NCT03796559 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Endomagnetics, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Magseed Marker is the first listed.

NCT03796559 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03796559 about?

NCT03796559 is a clinical study titled "Magseed Enabled Long-Term Localization of Axillary Lymph Nodes". The purpose of this study is to provide prospective evidence that the use of Magseed/Sentimag in marking axillary lymph nodes and guiding surgical localization in patients with breast cancer following neo-adjuvant chemotherapy (NAC) is effective.

What is the current status of trial NCT03796559?

This trial is currently recruiting. It is a NA study. The enrollment target is 65 participants. The study started on 2019-06-13. Estimated completion is 2026-05.

What conditions does trial NCT03796559 study?

This clinical trial studies the following conditions: Breast Cancer, Axillary Lymph Nodes.

What interventions are being tested in trial NCT03796559?

The interventions under investigation include: Magseed Marker (DEVICE).

Who is sponsoring clinical trial NCT03796559?

This trial is sponsored by Endomagnetics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03796559 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.